Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.04T
Market cap1.04T
Price-Earnings ratio
39.67
Price-Earnings ratio39.67
Dividend yield
0.59%
Dividend yield0.59%
Average volume
3.15M
Average volume3.15M
High today
$1,120.98
High today$1,120.98
Low today
$1,090.23
Low today$1,090.23
Open price
$1,117.08
Open price$1,117.08
Volume
2.00M
Volume2.00M
52 Week high
$1,182.73
52 Week high$1,182.73
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 1.04T, Eli Lilly(LLY) trades at $1,107.32. The stock has a price-to-earnings ratio of 39.67 and currently yields dividends of 0.59%.

On 2026-06-23, Eli Lilly(LLY) stock moved within a range of $1,090.23 to $1,120.98. With shares now at $1,107.32, the stock is trading +1.6% above its intraday low and -1.2% below the session's peak.

Trading activity shows a volume of 2M, compared to an average daily volume of 3.15M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

LLY News

Benzinga 1h
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle

Sangamo Therapeutics Inc. (NASDAQ:SGMO) filed for Chapter 11 bankruptcy protection on Tuesday, as the gene therapy company seeks to sell its assets through a co...

Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle
TipRanks 3h
Sangamo files for restructuring, plans asset sales to Lilly, Astellas

Sangamo Therapeutics (SGMO) announced that it has commenced voluntary Chapter 11 bankruptcy reorganization proceedings and entered into separate “stalking horse...

TipRanks 4h
Eli Lilly Opens Data Center to Smaller Biotech Firms as It Chases Drug Discoveries

Pharmaceutical giant Eli Lilly (LLY) is undertaking an innovative new strategy that will see it partner with scientists on new drug developments. Unlock powerf...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

The Motley Fool 5h
Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

GLP-1 drugs are proving helpful for many conditions, not just weight loss. In studies, they have shown they can reduce cardiovascular risk, sleep apnea, and eve...

Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?
Nasdaq 19h
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk

Key Points Viking Therapeutics has a weight-loss program that looks to be competitive with medicines already on the market. It's unclear how its candidate com...

Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
TipRanks 23h
Centessa announces High Court approval for acquisition by Eli Lilly

Centessa (CNTA) which entered into a definitive agreement relating to its proposed acquisition by Eli Lilly (LLY), through a wholly owned subsidiary, announced...

24/7 Wall St. 23h
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today . Lilly secured f...

Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow
TipRanks 1d
Eli Lilly price target raised to $1,135 from $1,050 at Berenberg

Berenberg analyst Kerry Holford raised the firm’s price target on Eli Lilly (LLY) to $1,135 from $1,050 and keeps a Hold rating on the shares. Unlock powerful...

TipRanks 1d
Cantor Fitzgerald Pounds the Table on Eli Lilly Stock Heading into Q2 Earnings Season

Wall Street brokerage Cantor Fitzgerald is pounding the table on Eli Lilly’s (LLY) stock as we head into second-quarter earnings season. Unlock powerful invest...

Simply Wall St 1d
Eli Lilly Teams Up With BioArctic On A New Neurodegeneration Therapy

Eli Lilly (NYSE:LLY) announced a new research and collaboration agreement with BioArctic AB to develop a neurodegeneration therapy using BioArctic's BrainTransp...

Eli Lilly Teams Up With BioArctic On A New Neurodegeneration Therapy

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.